

Market Outlook

The Nifty 50 ended the week at 25,492, extending the profit-booking phase from the 25,800 level and registering a weekly decline of 0.89%. On the daily chart, the index witnessed a rebound from the 25,300 zone, which aligns with the long-term 50-day EMA, indicating this level as a critical support area. On the derivatives front, fresh Put OI build-up at the 25,300 and 25,400 strike underscores the immediate support zone. Conversely, Call OI buildup at the 25,700 and 25,800 strikes suggests near-term hurdles, while strong resistance remains positioned at the 26,000 mark.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25492.30	-0.07
SENSEX	83216.28	-0.11
BANKNIFTY	57876.80	0.56
INDIA VIX	12.55	1.19

Flls STATISTICS


Flls F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-2721.16	7.12%
Index Options	11623.01	16.01%
Stock Futures	-1503.64	0.44%
Stock Options	-141.82	6.44%

Flls & Dlls Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	4581.34	-1633	-111853
DII	6674.76	16678	459128

Flls Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
BHARTIARTL	57886728	14.6	637.38
ETERNAL	13831648	-10.22	-39.83
HDFCBANK	10669610	19.94	-32.65
POWERGRID	8327537	11.31	-48.09
SBIN	7959780	1.5	-42.09
HINDALCO	7180413	-5.67	-62.09
ITC	5916918	9.39	-16.68
INFY	5814986	-0.33	10.33
NTPC	5777378	2.77	-25.97
BEL	5198138	-7.35	-20.69


NIFTY

Nifty	25589.20
OI (In contracts)	268677
CHANGE IN OI (%)	5.40
PRICE CHANGE (%)	-0.10
IMPLICATION	SHORT BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
LTF	304.7	10.20	11518	10.40
ADANIGREEN	1064.9	0.10	34158	8.40
BRITANNIA	6185	2.30	30456	7.10
LICI	928.7	3.40	13964	5.50
FORTIS	1022.7	1.20	13407	4.50


BANKNIFTY

Banknifty	58181.60
OI (In contracts)	57196
CHANGE IN OI (%)	-1.70
PRICE CHANGE (%)	0.50
IMPLICATION	SHORT COVERING

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
AMBER	6926.5	-10.20	14566	73.20
ABB	5002.5	-4.20	23390	22.50
BLUESTARCO	1760.5	-1.30	5797	11.90
CYIENT	1118	-2.50	10864	8.10
CUMMINSIND	4310.8	-0.60	15693	5.80

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
PETRONET	14898600	12481200	1.19
AUBANK	6748000	5727000	1.18
LTF	44314410	39100506	1.13
CANBK	108283500	97071750	1.12
IOC	58461000	53488500	1.09
BHEL	33568500	31363500	1.07
SHRIRAMFIN	17788650	16639425	1.07
POWERINDIA	264000	248450	1.06
BPCL	31364975	31090450	1.01
ALKEM	186250	187375	0.99

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
BHARTIARTL	9160375	29487050	0.31
BLUESTARCO	824200	2652000	0.31
NESTLEIND	1927000	5835500	0.33
GMRAIRPORT	41654700	123450525	0.34
SHREECEM	46325	127600	0.36
DELHIVERY	9310525	25368950	0.37
KAYNES	896400	2394700	0.37
MAZDOCK	1740400	4663225	0.37
PPLPHARMA	5670000	15082500	0.38
YESBANK	169152900	440655900	0.38

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2431	2481	2364	2314	2246
ADANIPORTS	1473	1491	1451	1433	1411
APOLLOHOSP	7848	8025	7749	7572	7473
ASIANPAINT	2626	2638	2604	2592	2571
AXISBANK	1235	1241	1229	1222	1216
BAJAJ-AUTO	8823	8888	8730	8666	8573
BAJAJFINSV	2139	2166	2094	2067	2022
BAJFINANCE	1090	1108	1064	1046	1020
BEL	421	425	413	409	402
BHARTIARTL	2040	2077	2018	1981	1959
CIPLA	1516	1523	1506	1500	1490
COALINDIA	380	382	376	374	371
DRREDDY	1211	1218	1204	1196	1190
EICHERMOT	6962	7019	6856	6799	6693
ETERNAL	311	315	307	303	299
GRASIM	2763	2789	2723	2697	2657
HCLTECH	1529	1542	1513	1499	1483
HDFCBANK	992	996	986	981	975
HDFCLIFE	759	767	745	737	722
HINDALCO	805	817	795	784	774
HINDUNILVR	2435	2446	2422	2411	2399
ICICIBANK	1356	1364	1340	1332	1317
INDIGO	5694	5779	5644	5558	5508
INFY	1473	1485	1454	1441	1423
ITC	409	413	407	404	402

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	304	306	299	296	292
JSWSTEEL	1192	1207	1173	1159	1140
KOTAKBANK	2115	2131	2090	2073	2048
LT	3925	3950	3887	3861	3823
M&M	3757	3817	3666	3606	3515
MARUTI	15627	15718	15479	15388	15240
MAXHEALTH	1147	1156	1136	1128	1117
NESTLEIND	1275	1285	1267	1257	1249
NTPC	329	332	326	323	319
ONGC	254	256	252	250	248
POWERGRID	270	272	267	266	263
RELIANCE	1497	1509	1489	1477	1469
SBILIFE	2013	2026	1991	1979	1957
SBIN	968	977	957	948	937
SHRIRAMFIN	832	846	808	794	770
SUNPHARMA	1709	1724	1698	1683	1672
TATACONSUM	1186	1202	1174	1158	1145
TATASTEEL	185	187	180	177	173
TCS	3019	3041	2994	2972	2947
TECHM	1409	1425	1400	1383	1374
TITAN	3808	3833	3780	3754	3726
TMPV	408	411	405	402	399
TRENT	4703	4769	4661	4595	4553
ULTRACEMCO	11985	12064	11930	11851	11796
WIPRO	240	242	238	236	234

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results